AAAAAA

   
Results: 1-16 |
Results: 16
TAMOXIFEN IN LIVER-DISEASE - POTENTIAL EXACERBATION OF HEPATIC-DYSFUNCTION
Authors: FLOREN LC HEBERT MF VENOOK AP JORDAN VC CISNEROS A SOMBERG KA
Citation: Lc. Floren et al., TAMOXIFEN IN LIVER-DISEASE - POTENTIAL EXACERBATION OF HEPATIC-DYSFUNCTION, Annals of oncology, 9(10), 1998, pp. 1123-1126
CONTRIBUTIONS OF HEPATIC AND INTESTINAL METABOLISM AND P-GLYCOPROTEINTO CYCLOSPORINE AND TACROLIMUS ORAL-DRUG DELIVERY
Authors: HEBERT MF
Citation: Mf. Hebert, CONTRIBUTIONS OF HEPATIC AND INTESTINAL METABOLISM AND P-GLYCOPROTEINTO CYCLOSPORINE AND TACROLIMUS ORAL-DRUG DELIVERY, Advanced drug delivery reviews, 27(2-3), 1997, pp. 201-214
TACROLIMUS ORAL BIOAVAILABILITY DOUBLES WITH COADMINISTRATION OF KETOCONAZOLE
Authors: FLOREN LC BEKERSKY I BENET LZ MEKKI Q DRESSLER D LEE JW ROBERTS JP HEBERT MF
Citation: Lc. Floren et al., TACROLIMUS ORAL BIOAVAILABILITY DOUBLES WITH COADMINISTRATION OF KETOCONAZOLE, Clinical pharmacology and therapeutics, 62(1), 1997, pp. 41-49
INTESTINAL DRUG-METABOLISM AND ANTITRANSPORT PROCESSES - A POTENTIAL PARADIGM SHIFT IN ORAL-DRUG DELIVERY
Authors: BENET LZ WU CY HEBERT MF WACHER VJ
Citation: Lz. Benet et al., INTESTINAL DRUG-METABOLISM AND ANTITRANSPORT PROCESSES - A POTENTIAL PARADIGM SHIFT IN ORAL-DRUG DELIVERY, Journal of controlled release, 39(2-3), 1996, pp. 139-143
THE EFFECT OF WATER-SOLUBLE VITAMIN-E ON CYCLOSPORINE PHARMACOKINETICS IN HEALTHY-VOLUNTEERS
Authors: CHANG T BENET LZ HEBERT MF
Citation: T. Chang et al., THE EFFECT OF WATER-SOLUBLE VITAMIN-E ON CYCLOSPORINE PHARMACOKINETICS IN HEALTHY-VOLUNTEERS, Clinical pharmacology and therapeutics, 59(3), 1996, pp. 297-303
PHARMACOKINETICS (PK) OF INTRAVENOUS MYCOPHENOLATE MOFETIL (MMF) IN LIVER-TRANSPLANT PATIENTS
Authors: HEBERT MF CHANG T LINNA TJ HALE MD ROBERTS JP
Citation: Mf. Hebert et al., PHARMACOKINETICS (PK) OF INTRAVENOUS MYCOPHENOLATE MOFETIL (MMF) IN LIVER-TRANSPLANT PATIENTS, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 101-101
DIFFERENTIATION OF ABSORPTION AND FIRST-PASS GUT AND HEPATIC-METABOLISM IN HUMANS - STUDIES WITH CYCLOSPORINE
Authors: WU CY BENET LZ HEBERT MF GUPTA SK ROWLAND M GOMEZ DY WACHER VJ
Citation: Cy. Wu et al., DIFFERENTIATION OF ABSORPTION AND FIRST-PASS GUT AND HEPATIC-METABOLISM IN HUMANS - STUDIES WITH CYCLOSPORINE, Clinical pharmacology and therapeutics, 58(5), 1995, pp. 492-497
THE EFFECTS OF KETOCONAZOLE ON THE INTESTINAL METABOLISM AND BIOAVAILABILITY OF CYCLOSPORINE
Authors: GOMEZ DY WACHER VJ TOMLANOVICH SJ HEBERT MF BENET LZ
Citation: Dy. Gomez et al., THE EFFECTS OF KETOCONAZOLE ON THE INTESTINAL METABOLISM AND BIOAVAILABILITY OF CYCLOSPORINE, Clinical pharmacology and therapeutics, 58(1), 1995, pp. 15-19
PHARMACOKINETICS OF TACROLIMUS IN LIVER-TRANSPLANT PATIENTS
Authors: JUSKO WJ PIEKOSZEWSKI W KLINTMALM GB SHAEFER MS HEBERT MF PIERGIES AA LEE CC SCHECHTER P MEKKI QA
Citation: Wj. Jusko et al., PHARMACOKINETICS OF TACROLIMUS IN LIVER-TRANSPLANT PATIENTS, Clinical pharmacology and therapeutics, 57(3), 1995, pp. 281-290
THE EFFECT OF WATER-SOLUBLE VITAMIN-E (TPGS) ON ORAL CYCLOSPORINE PHARMACOKINETICS IN HEALTHY-VOLUNTEERS
Authors: CHANG T BENET LZ HEBERT MF
Citation: T. Chang et al., THE EFFECT OF WATER-SOLUBLE VITAMIN-E (TPGS) ON ORAL CYCLOSPORINE PHARMACOKINETICS IN HEALTHY-VOLUNTEERS, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 163-163
ORAL PROGESTERONE THERAPY DOES NOT AFFECT THE PHARMACOKINETICS OF PREDNISOLONE AND ERYTHROMYCIN IN POSTMENOPAUSAL WOMEN
Authors: TSUNODA SM HARRIS RZ MROCZKOWSKI PJ HEBERT MF BENET LZ
Citation: Sm. Tsunoda et al., ORAL PROGESTERONE THERAPY DOES NOT AFFECT THE PHARMACOKINETICS OF PREDNISOLONE AND ERYTHROMYCIN IN POSTMENOPAUSAL WOMEN, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 182-182
CYCLOSPORINE PHARMACOKINETICS PRE-LIVER AND POST-LIVER TRANSPLANTATION
Authors: HEBERT MF WACHER VJ BENET LZ
Citation: Mf. Hebert et al., CYCLOSPORINE PHARMACOKINETICS PRE-LIVER AND POST-LIVER TRANSPLANTATION, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 187-187
FOCUS ON TACROLIMUS - A NEW MACROLIDE IMMUNOSUPPRESSIVE AGENT FOR LIVER-TRANSPLANT RECIPIENTS
Authors: HEBERT MF ROBERTS JP
Citation: Mf. Hebert et Jp. Roberts, FOCUS ON TACROLIMUS - A NEW MACROLIDE IMMUNOSUPPRESSIVE AGENT FOR LIVER-TRANSPLANT RECIPIENTS, Hospital formulary, 29(6), 1994, pp. 447
A COMPARISON OF TACROLIMUS (FK-506) AND CYCLOSPORINE FOR IMMUNOSUPPRESSION IN LIVER-TRANSPLANTATION
Authors: BUSUTTIL RW MCDIARMID S KLINTMALM GB GOLDSTEIN R MILLER CM SCHWARTZ M SHAW BW ROBERTS JP HEBERT MF ESQUIVEL CO NAKAZATO P WIESNER RH KROM RAF KALAYOGLU M DALESSANDRO AM MARSH JW PETERS MG BURDICK J KLEIN A LEWIS WD JENKINS R THISTLETHWAITE JR EMOND JC JUSKO WJ DAMBROSIO R BUELL D FITZSIMMONS WE
Citation: Rw. Busuttil et al., A COMPARISON OF TACROLIMUS (FK-506) AND CYCLOSPORINE FOR IMMUNOSUPPRESSION IN LIVER-TRANSPLANTATION, The New England journal of medicine, 331(17), 1994, pp. 1110-1115
PHARMACOKINETICS (PK) OF ORAL MYCOPHENOLATE MOFETIL (MM) IN LIVER-TRANSPLANT PATIENTS
Authors: HEBERT MF BENET LZ GOMEZ D LEE R LINNA TJ SHAH J ROBERTS JP
Citation: Mf. Hebert et al., PHARMACOKINETICS (PK) OF ORAL MYCOPHENOLATE MOFETIL (MM) IN LIVER-TRANSPLANT PATIENTS, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 164-164
END-STAGE LIVER-DISEASE ASSOCIATED WITH NITROFURANTOIN REQUIRING LIVER-TRANSPLANTATION
Authors: HEBERT MF ROBERTS JP
Citation: Mf. Hebert et Jp. Roberts, END-STAGE LIVER-DISEASE ASSOCIATED WITH NITROFURANTOIN REQUIRING LIVER-TRANSPLANTATION, The Annals of pharmacotherapy, 27(10), 1993, pp. 1193-1194
Risultati: 1-16 |